吉非替尼对非小细胞肺癌脑转移的预后分析

Effects of gefitinib on the prognosis of patients with non-small cell lung cancer brain metastases

目的探讨吉非替尼对EGFR突变(+)非小细胞肺癌脑转移预后的影响。方法回顾性分析我院收治的70例EGFR突变(+)非小细胞肺癌脑转移患者的临床资料,根据治疗方法不同分为治疗组和对照组各35例,其中对照组给予常规全脑放疗,治疗组在对照组的基础上给予吉非替尼治疗,比较2组临床效果和不良反应发生情况。结果治疗后治疗组有效率48.57%,显著高于对照组的34.28%(P<0.05);治疗组疾病控制率77.14%,显著高于对照组的60.00%(P<0.05);治疗组CR率17.14%,显著高于对照组的8.57%,治疗组PD率22.86%,显著低于对照组的40.00%(P<0.05);治疗组不良反应发生率45.71%,对照组42.86%,2组比较无显著差异(P>0.05)。结论吉非替尼联合全脑放疗治疗EGFR突变(+)非小细胞肺癌脑转移患者不良反应小,临床效果显著。

Objective To investigate the effects of gefitinib on the prognosis of patients with non-small cell lung cancer brain metastases. Methods The clinical data of 70 patients with non-small cell lung cancer brain metastases in our hospital were retrospectively analyzed. Patients were divided into the treatment group （n=35 ,treated with whole brain radiotherapy ） and the control group （n=35 ,treated with whole brain radiotherapy combined with gefitinib ） according to the different treat-ment methods. The curative effects and adverse reactions were compared. Results The efficiency （48.57% ） ,disease control rate （77.14% ） and CR patients （17.14% ） of treatment group were higher than these of control group （34.28% ,60.00% and 8.57% ） ,respectively ;The PD rate （22.86% ） of treatment group was lower than that of control group ;The adverse reaction incidence between two groups had no significant difference. Conclusion Gefitinib combined with whole brain radiotherapy have less toxic side effects and better curative effect on patients with non-small cell lung cancer brain metastases.